COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines

被引:401
|
作者
Meo, S. A. [1 ]
Bukhari, I. A. [2 ]
Akram, J. [3 ]
Meo, A. S. [4 ]
Klonoff, D. C. [5 ]
机构
[1] King Saud Univ, Coll Med, Dept Physiol, Riyadh, Saudi Arabia
[2] King Saud Univ, Coll Med, Dept Pharmacol, Riyadh, Saudi Arabia
[3] Univ Hlth Sci, Dept Med, Lahore, Pakistan
[4] Natl Univ Med Sci, Army Med Coll, Rawalpindi, Pakistan
[5] Mills Peninsula Med Ctr, Diabet Res Inst, San Mateo, CA USA
关键词
SARS-CoV-2; vaccine; Pfizer/BioNTech; Moderna vaccine; Pharmacology; Adverse effects; PREVALENCE;
D O I
10.26355/eurrev_202102_24877
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: The "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" disease has caused a worldwide challenging and threatening pandemic (COVID-19), with huge health and economic losses. The US Food and Drug Administration, (FDA) has granted emergency use authorization for treatment with the Pfizer/BioNTech and Moderna COVID-19 vaccines. Many people have a history of a significant allergic reaction to a specific food, medicine, or vaccine; hence, people all over the world have great concerns about these two authorized vaccines. This article compares the pharmacology, indications, contraindications, and adverse effects of the Pfizer/BioNTech and Moderna vaccines. MATERIALS AND METHODS: The required documents and information were collected from the relevant databases, including Web of Science (Clarivate Analytics), PubMed, EMBASE, World Health Organization (WHO), Food and Drug Authorities (FDA) USA, Local Ministries, Health Institutes, and Google Scholar. The key terms used were: Coronavirus, SARS-COV-2, COVID-19 pandemic, vaccines, Pfizer/BioNTech vaccine, Moderna vaccine, pharmacology, benefits, allergic responses, indications, contraindications, and adverse effects. The descriptive information was recorded, and we eventually included 12 documents including research articles, clinical trials, and websites to record the required information. RESULTS: Based on the currently available literature, both vaccines are beneficial to provide immunity against SARS-CoV-2 infection. Pfizer/BioNTech Vaccine has been recommended to people 16 years of age and older, with a dose of 30 mu g (0.3 m) at a cost of $19.50. It provides immunogenicity for at least 119 days after the first vaccination and is 95% effective in preventing the SARS-COV-2 infection. However, Moderna Vaccine has been recommended to people 18 years of age and older, with a dose of 50 mu g (0.5 mL) at a cost of $32-37. It provides immunogenicity for at least 119 days after the first vaccination and is 94.5% effective in preventing the SARS-CoV-2 infection. However, some associated allergic symptoms have been reported for both vaccines. The COVID-19 vaccines can cause mild adverse effects after the first or second doses, including pain, redness or swelling at the site of vaccine shot, fever, fatigue, headache, muscle pain, nausea, vomiting, itching, chills, and joint pain, and can also rarely cause anaphylactic shock. The occurrence of adverse effects is reported to be lower in the Pfizer/BioNTech vaccine compared to the Moderna vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive. CONCLUSIONS: The FDA has granted emergency use authorization for the Pfizer/BioNTech and Moderna COVID-19 vaccines. These vaccines can protect recipients from a SARS-CoV-2 infection by formation of antibodies and provide immunity against a SARS-CoV-2 infection. Both vaccines can cause various adverse effects, but these reactions are reported to be less frequent in the Pfizer/BioNTech vaccine compared to the Moderna COVID-19 vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.
引用
收藏
页码:1663 / 1669
页数:7
相关论文
共 50 条
  • [3] COVID-19 Vaccines: Moderna And Pfizer-BioNTech Use Varied By Urban, Rural Counties
    Wen, Katherine
    Harris, Daniel A.
    Chachlani, Preeti
    Hayes, Kaleen N.
    Mccarthy, Ellen
    Zullo, Andrew R.
    Smith-Ray, Renae L.
    Singh, Tanya
    Djibo, Djeneba Audrey
    McMahill-Walraven, Cheryl N.
    Hiris, Jeffrey
    Conti, Rena M.
    Gruber, Jonathan
    Mor, Vincent
    [J]. HEALTH AFFAIRS, 2024, 43 (05) : 659 - 665
  • [4] Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines
    Sessa, Maurizio
    Kragholm, Kristian
    Hviid, Anders
    Andersen, Morten
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (11) : 1451 - 1453
  • [6] Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines
    Noor, Rashed
    [J]. CURRENT CLINICAL MICROBIOLOGY REPORTS, 2021, 8 (03) : 178 - 185
  • [7] Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines
    Rashed Noor
    [J]. Current Clinical Microbiology Reports, 2021, 8 : 178 - 185
  • [8] The Effect of Third Dose of Pfizer/BioNTech and Moderna COVID-19 mRNA Vaccines on IgG Antibody Titers
    Khuc, Thao A.
    Pequeno, Gregery
    Betancourt-Garcia, Monica
    Casciato, Adrienne M.
    Gomez-Martinez, Marissa
    Arroyo, Carlos D.
    Pope, Bill D., III
    Narmala, Shravan
    Rao, Sohail
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [9] Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines
    Marcec, Robert
    Likic, Robert
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2022, 98 (1161) : 544 - 550
  • [10] Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1660): : 159 - 160